VIMTA LABS LIMITED Intrinsic Value
VIMTALABS · Healthcare · Current price ₹662.95
Is VIMTA LABS LIMITED undervalued?
DocStoX estimates the fair value of VIMTA LABS LIMITED at ₹468 per share, versus the current market price of ₹663. That puts the stock about -29.4% above our fair-value estimate, which we read as "Avoid". Our confidence in this estimate is low.
How this fair value is calculated
This estimate blends 4 independent methods: Residual income (₹109), Relative P/E (₹1,122), Graham floor (₹199), Analyst target (₹744). We weight each by its reliability and skip any method whose inputs look untrustworthy — "no DCF beats a wrong DCF". This is the same deterministic engine that powers DocStoX stock pages; there is no guesswork or AI-generated number here.
Bear, base and bull scenarios
Our scenarios span ₹109 (bear) to ₹468 (base) to ₹1,122 (bull). A margin of safety means buying meaningfully below the base case — the wider the gap, the more room for error in the assumptions.
Margin of safety
Value investors demand a margin of safety — a discount to intrinsic value that protects against being wrong. At ₹663 versus an intrinsic value of ₹468, VIMTA LABS LIMITED currently offers -29.4% of negative margin (i.e. a premium).
More on VIMTA LABS LIMITED
DocStoX estimates are generated by a deterministic valuation engine from reported financials — for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.